- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02619994
Treatment Shortening of MDR-TB Using Existing and New Drugs (MDR-END)
January 31, 2019 updated by: Jae-Joon Yim, Seoul National University Hospital
Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial
The purpose of this study is to compare the efficacy of a 'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24 months (control arm)' for treating fluoroquinolone-sensitive multidrug-resistant tuberculosis.
Study Overview
Status
Unknown
Conditions
Detailed Description
This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB.
The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20-24 months.
The investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture conversion.
The primary outcome is the treatment success rate at 24 months after treatment initiation.
Secondary outcomes include time to sputum culture conversion on liquid and solid media, proportions of sputum culture conversion on liquid media after 2 and 6 months of treatment, treatment success rate according to pyrazinamide resistance, and occurrence of adverse events grade 3 and above as evaluated by the Common Terminology Criteria for Adverse Events.
The population number is calculated as 102 per group (204 in total).
Study Type
Interventional
Enrollment (Anticipated)
238
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jae-Joon Yim, MD
- Phone Number: +82-2-2072-2059
- Email: yimjj@snu.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Recruiting
- Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine
-
Contact:
- Jae-Joon Yim, MD
- Phone Number: +82-2-2072-2059
- Email: yimjj@snu.ac.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females aged from 19 to 85 years
- Confirmed MDR-TB or RR-TB
- On current TB therapy for ≤14 days at the time of enrollment.
Exclusion Criteria:
- Known any quinolone-resistant MDR-TB
- Known XDR-TB
- who are pregnant or who are unwilling to use proper contraceptives at childbearing age
- Medical history of galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- The need for ongoing use of prohibited drugs while on study drugs
- History of optic neuropathy or peripheral neuropathy
- With any of the following test results: i.Absolute neutrophil count < 2000 cells/mL, ii.White blood cell count (WBC) < 3.0 X 103/µL, iii.Hemoglobin < 7.0 g/dL, iv.Serum creatinine > 2.0 mg/dL, v.Aspartate aminotransferase (AST or SGOT) >100 IU/L, vi.Alanine aminotransferase (ALT or SGPT) >100 IU/L, vii.Total bilirubin > 2.0 mg/dL, viii.Albumin < 2.8g/dL, ix.QTcF > 500ms
- History of hypersensitivity reaction to the study drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Arm
Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.
|
|
Experimental: Experimental Arm
Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment success rate
Time Frame: 24 months after treatment start
|
To test for non-inferiority of the investigational arm, when the lower limit of the one-sided 97.5% confidence interval of the difference (PT - PC) between investigational and control arms is larger than the non-inferiority margin of - 10%, it will be concluded that the treatment success rate of the investigational arm shows non-inferiority to the treatment success rate of the control arm.
|
24 months after treatment start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to sputum culture conversion after treatment start
Time Frame: through study completion, 24 months after enrollment
|
To determine whether time to sputum culture conversion after treatment start is statis- tically different between the control and investigational arms, the median time will be estimated in each group using the Kaplan-Meier method, and the difference in the distribution of time to culture conversion of the two arms will be compared using the log-rank test.
|
through study completion, 24 months after enrollment
|
Sputum culture conversion proportion
Time Frame: At 2 months or 6 months of treatment
|
At 2 months or 6 months of treatment
|
|
Treatment success
Time Frame: At 24months after enrollment
|
At 24months after enrollment
|
|
proportion of reverting to positive sputum culture after the end of treatment
Time Frame: At 24months after enrollment
|
At 24months after enrollment
|
|
Treatment success according to pyrazinamide resistance
Time Frame: At 24months after enrollment
|
At 24months after enrollment
|
|
proportion of death between the control and investigational arms
Time Frame: At 24months after enrollment
|
At 24months after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Anticipated)
June 1, 2021
Study Completion (Anticipated)
June 1, 2021
Study Registration Dates
First Submitted
November 24, 2015
First Submitted That Met QC Criteria
November 30, 2015
First Posted (Estimate)
December 2, 2015
Study Record Updates
Last Update Posted (Actual)
February 4, 2019
Last Update Submitted That Met QC Criteria
January 31, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Multidrug-Resistant
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Antitubercular Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Linezolid
- Levofloxacin
- Ofloxacin
- Pyrazinamide
Other Study ID Numbers
- MDR-END
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis, Multidrug-Resistant
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug-resistant TuberculosisSouth Africa, Estonia, Philippines, Peru, Lithuania, Latvia, Moldova, Republic of
-
Janssen Research & Development, LLCRecruitingMultidrug-Resistant TuberculosisMozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
-
University of Cape TownBaylor Research InstituteCompletedMultidrug-resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingTuberculosis, MDRHaiti, Tanzania, Thailand, Botswana, Brazil, India, Kenya, Peru, Philippines, South Africa, Uganda, Zimbabwe, Vietnam
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedTuberculosisLatvia, Lithuania
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug Resistant TuberculosisPhilippines, South Africa
-
Huashan HospitalUnknownMultidrug Resistant TuberculosisChina
Clinical Trials on Levofloxacin
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
University of KarachiMerck Pvt. Ltd, Pakistan; Center for bioequivalence studies and clinical reseach...Completed
-
University of RochesterCompletedChronic RhinosinusitisUnited States
-
Indonesia UniversityEnrolling by invitationUrinary Tract InfectionsIndonesia
-
University of MonastirCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
University of MonastirCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
Indiana University School of MedicineCompletedCataractUnited States
-
InnocollPremier Research Group plcCompletedDiabetic Foot UlcerUnited States
-
Mackay Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
University of LatviaNational Institute of Public Health, Slovenia; Iuliu Hatieganu University of... and other collaboratorsRecruitingGastric Cancer | H Pylori Infection | H Pylori Eradication | H-pyloriPoland, Croatia, Ireland, Latvia, Romania, Slovenia